Interventional surgery, compared to traditional surgical procedures, has advantages such as less trauma, fewer postoperative complications, and shorter treatment times. Neurointerventional technology is mainly used to treat cerebrovascular and spinal vascular diseases. Due to its high technical barriers and wide range of applications, it is hailed as the pearl on the crown of interventional surgery. With the annual increase in the number of patients with cerebrovascular diseases, the harm caused is becoming increasingly serious. The attention from all sectors of society towards cerebrovascular diseases is growing day by day, making it urgent to carry out education on the prevention and treatment of chronic diseases such as stroke.
Frost & Sullivan (Frost & Sullivan, abbreviated as 'Frost & Sullivan') officially released the 'White Paper on the Current Industry Situation and Future Development of the Neurointerventional Industry in China' (hereinafter referred to as the 'Report') on March 16, 2023. Starting from neurointerventional technology, the Report sorts out the basic principles of neurointerventional technology, diseases it targets, existing treatment plans, and key companies. Its aim is to analyze the overall industry landscape of neurointerventional technology, including current development status, industry characteristics, treatment areas, and driving factors. It also focuses on the competitive market situation in the Chinese neurointerventional industry, reflecting the differentiated competitive advantages of the leading enterprises in this market echelon.
